Endothelial dysfunction and specific inflammation in obesity hypoventilation syndrome

Jean-Christian Borel, Pascale Roux-Lombard, Renaud Tamisier, Claire Arnaud, Denis Monneret, Nathalie Arnol, Jean-Philippe Baguet, Patrick Levy, Jean-Louis Pepin, Jean-Christian Borel, Pascale Roux-Lombard, Renaud Tamisier, Claire Arnaud, Denis Monneret, Nathalie Arnol, Jean-Philippe Baguet, Patrick Levy, Jean-Louis Pepin

Abstract

Background: Obesity hypoventilation syndrome (OHS) is associated with increased cardiovascular morbidity. What moderate chronic hypoventilation adds to obesity on systemic inflammation and endothelial dysfunction remains unknown.

Question: To compare inflammatory status and endothelial function in OHS versus eucapnic obese patients.

Methodology: 14 OHS and 39 eucapnic obese patients matched for BMI and age were compared. Diurnal blood gazes, overnight polysomnography and endothelial function, measured by reactive hyperemia peripheral arterial tonometry (RH-PAT), were assessed. Inflammatory (Leptin, RANTES, MCP-1, IL-6, IL-8, TNFalpha, Resistin) and anti-inflammatory (adiponectin, IL-1Ra) cytokines were measured by multiplex beads immunoassays.

Principal findings: OHS exhibited a higher PaCO(2), a lower forced vital capacity (FVC) and tended to have a lower PaO(2) than eucapnic obese patients. (HS)-CRP, RANTES levels and glycated haemoglobin (HbA1c) were significantly increased in OHS (respectively 11.1+/-10.9 vs. 5.7+/-5.5 mg x l(-1) for (HS)-CRP, 55.9+/-55.3 vs 23.3+/-15.8 ng/ml for RANTES and 7.3+/-4.3 vs 6.1+/-1.7 for HbA1c). Serum adiponectin was reduced in OHS (7606+/-2977 vs 13,660+/-7854 ng/ml). Endothelial function was significantly more impaired in OHS (RH-PAT index: 0.22+/-0.06 vs 0.51+/-0.11).

Conclusions: Compared to eucapnic obesity, OHS is associated with a specific increase in the pro-atherosclerotic RANTES chemokine, a decrease in the anti-inflammatory adipokine adiponectin and impaired endothelial function. These three conditions are known to be strongly associated with an increased cardiovascular risk.

Trial registration: ClinicalTrials.gov NCT00603096.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1. Comparison between Obesity Hypoventilation Syndrome…
Figure 1. Comparison between Obesity Hypoventilation Syndrome (OHS) compared to eucapnic obese patients in RH-PAT, Sleep time spent with SpO2
TST: total sleep time.

References

    1. Kaw R, Hernandez AV, Walker E, Aboussouan L, Mokhlesi B. Determinants of Hypercapnia in Obese Patients With Obstructive Sleep Apnea. A Systematic Review and Metaanalysis of Cohort Studies. Chest. 2009 June 30 [Epub ahead of print], DOI 10.1378/chest.09-0615.
    1. Mokhlesi B, Tulaimat A. Recent advances in obesity hypoventilation syndrome. Chest. 2007;132:1322–1336.
    1. Olson AL, Zwillich C. The obesity hypoventilation syndrome. Am J Med. 2005;118:948–956.
    1. Berg G, Delaive K, Manfreda J, Walld R, Kryger MH. The use of health-care resources in obesity-hypoventilation syndrome. Chest. 2001;120:377–383.
    1. Perez de Llano LA, Golpe R, Ortiz Piquer M, Veres Racamonde A, Vazquez Caruncho M, et al. Short-term and long-term effects of nasal intermittent positive pressure ventilation in patients with obesity-hypoventilation syndrome. Chest. 2005;128:587–594.
    1. Nowbar S, Burkart KM, Gonzales R, Fedorowicz A, Gozansky WS, et al. Obesity-associated hypoventilation in hospitalized patients: prevalence, effects, and outcome. Am J Med. 2004;116:1–7.
    1. Apovian CM, Bigornia S, Mott M, Meyers MR, Ulloor J, et al. Adipose macrophage infiltration is associated with insulin resistance and vascular endothelial dysfunction in obese subjects. Arterioscler Thromb Vasc Biol. 2008;28:1654–1659.
    1. Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444:860–867.
    1. Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest. 2007;117:175–184.
    1. Schenk S, Saberi M, Olefsky JM. Insulin sensitivity: modulation by nutrients and inflammation. J Clin Invest. 2008;118:2992–3002.
    1. Pankow W, Hijjeh N, Schuttler F, Penzel T, Becker HF, et al. Influence of noninvasive positive pressure ventilation on inspiratory muscle activity in obese subjects. Eur Respir J. 1997;10:2847–2852.
    1. Vassilakopoulos T, Hussain SN. Ventilatory muscle activation and inflammation: cytokines, reactive oxygen species, and nitric oxide. J Appl Physiol. 2007;102:1687–1695.
    1. Vassilakopoulos T, Katsaounou P, Karatza MH, Kollintza A, Zakynthinos S, et al. Strenuous resistive breathing induces plasma cytokines: role of antioxidants and monocytes. Am J Respir Crit Care Med. 2002;166:1572–1578.
    1. Somers VK, White DP, Amin R, Abraham WT, Costa F, et al. Sleep apnea and cardiovascular disease: an American Heart Association/american College Of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council On Cardiovascular Nursing. In collaboration with the National Heart, Lung, and Blood Institute National Center on Sleep Disorders Research (National Institutes of Health). Circulation. 2008;118:1080–1111.
    1. Hosogai N, Fukuhara A, Oshima K, Miyata Y, Tanaka S, et al. Adipose tissue hypoxia in obesity and its impact on adipocytokine dysregulation. Diabetes. 2007;56:901–911.
    1. Pasarica M, Sereda OR, Redman LM, Albarado DC, Hymel DT, et al. Reduced adipose tissue oxygenation in human obesity: evidence for rarefaction, macrophage chemotaxis, and inflammation without an angiogenic response. Diabetes. 2009;58:718–725.
    1. Campo A, Fruhbeck G, Zulueta JJ, Iriarte J, Seijo LM, et al. Hyperleptinaemia, respiratory drive and hypercapnic response in obese patients. Eur Respir J. 2007;30:223–231.
    1. Phipps PR, Starritt E, Caterson I, Grunstein RR. Association of serum leptin with hypoventilation in human obesity. Thorax. 2002;57:75–76.
    1. Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol. 2005;115:911–919; quiz 920.
    1. Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. Sleep. 1999;22:667–689. The Report of an American Academy of Sleep Medicine Task Force.
    1. Rechtschaffen AKA. A manual of standardized terminology, techniques and scoring system for sleep stages in human subjects 1968.
    1. Chouri-Pontarollo N, Borel JC, Tamisier R, Wuyam B, Levy P, et al. Impaired objective daytime vigilance in obesity-hypoventilation syndrome: impact of noninvasive ventilation. Chest. 2007;131:148–155.
    1. Pepin JL, Delavie N, Pin I, Deschaux C, Argod J, et al. Pulse transit time improves detection of sleep respiratory events and microarousals in children. Chest. 2005;127:722–730.
    1. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, et al. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J. 1993;(Suppl 16):5–40.
    1. Read DJ. A clinical method for assessing the ventilatory response to carbon dioxide. Australas Ann Med. 1967;16:20–32.
    1. Bonetti PO, Pumper GM, Higano ST, Holmes DR, Jr, Kuvin JT, et al. Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia. J Am Coll Cardiol. 2004;44:2137–2141.
    1. Nohria A, Gerhard-Herman M, Creager MA, Hurley S, Mitra D, et al. Role of nitric oxide in the regulation of digital pulse volume amplitude in humans. J Appl Physiol. 2006;101:545–548.
    1. Hamburg NM, Keyes MJ, Larson MG, Vasan RS, Schnabel R, et al. Cross-sectional relations of digital vascular function to cardiovascular risk factors in the Framingham Heart Study. Circulation. 2008;117:2467–2474.
    1. Devouassoux G, Levy P, Rossini E, Pin I, Fior-Gozlan M, et al. Sleep apnea is associated with bronchial inflammation and continuous positive airway pressure-induced airway hyperresponsiveness. J Allergy Clin Immunol. 2007;119:597–603.
    1. Fabbri LM, Luppi F, Beghe B, Rabe KF. Complex chronic comorbidities of COPD. Eur Respir J. 2008;31:204–212.
    1. Krohn R, Raffetseder U, Bot I, Zernecke A, Shagdarsuren E, et al. Y-box binding protein-1 controls CC chemokine ligand-5 (CCL5) expression in smooth muscle cells and contributes to neointima formation in atherosclerosis-prone mice. Circulation. 2007;116:1812–1820.
    1. Koh SJ, Kim JY, Hyun YJ, Park SH, Chae JS, et al. Association of serum RANTES concentrations with established cardiovascular risk markers in middle-aged subjects. Int J Cardiol 2008
    1. Gurbel PA, Kreutz RP, Bliden KP, DiChiara J, Tantry US. Biomarker analysis by fluorokine multianalyte profiling distinguishes patients requiring intervention from patients with long-term quiescent coronary artery disease: a potential approach to identify atherosclerotic disease progression. Am Heart J. 2008;155:56–61.
    1. Kraaijeveld AO, de Jager SC, de Jager WJ, Prakken BJ, McColl SR, et al. CC chemokine ligand-5 (CCL5/RANTES) and CC chemokine ligand-18 (CCL18/PARC) are specific markers of refractory unstable angina pectoris and are transiently raised during severe ischemic symptoms. Circulation. 2007;116:1931–1941.
    1. Juge-Aubry CE, Henrichot E, Meier CA. Adipose tissue: a regulator of inflammation. Best Pract Res Clin Endocrinol Metab. 2005;19:547–566.
    1. Weber C. Platelets and chemokines in atherosclerosis: partners in crime. Circ Res. 2005;96:612–616.
    1. Schafer A, Pfrang J, Neumuller J, Fiedler S, Ertl G, et al. The cannabinoid receptor-1 antagonist rimonabant inhibits platelet activation and reduces pro-inflammatory chemokines and leukocytes in Zucker rats. Br J Pharmacol. 2008;154:1047–1054.
    1. Herder C, Illig T, Baumert J, Muller M, Klopp N, et al. RANTES/CCL5 gene polymorphisms, serum concentrations, and incident type 2 diabetes: results from the MONICA/KORA Augsburg case-cohort study, 1984-2002. Eur J Endocrinol. 2008;158:R1–5.
    1. Han SH, Quon MJ, Kim JA, Koh KK. Adiponectin and cardiovascular disease: response to therapeutic interventions. J Am Coll Cardiol. 2007;49:531–538.
    1. Okamoto Y, Folco EJ, Minami M, Wara AK, Feinberg MW, et al. Adiponectin inhibits the production of CXC receptor 3 chemokine ligands in macrophages and reduces T-lymphocyte recruitment in atherogenesis. Circ Res. 2008;102:218–225.
    1. Kumada M, Kihara S, Sumitsuji S, Kawamoto T, Matsumoto S, et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol. 2003;23:85–89.
    1. Arkin JM, Alsdorf R, Bigornia S, Palmisano J, Beal R, et al. Relation of cumulative weight burden to vascular endothelial dysfunction in obesity. Am J Cardiol. 2008;101:98–101.
    1. Ouchi N, Ohishi M, Kihara S, Funahashi T, Nakamura T, et al. Association of hypoadiponectinemia with impaired vasoreactivity. Hypertension. 2003;42:231–234.
    1. Celermajer DS, Sorensen KE, Bull C, Robinson J, Deanfield JE. Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. J Am Coll Cardiol. 1994;24:1468–1474.
    1. Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction: testing and clinical relevance. Circulation. 2007;115:1285–1295.
    1. Gokce N, Keaney JF,, Jr, Hunter LM, Watkins MT, Nedeljkovic ZS, et al. Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events in patients with peripheral vascular disease. J Am Coll Cardiol. 2003;41:1769–1775.
    1. Lavie L, Lavie P. Molecular mechanisms of cardiovascular disease in OSAHS: the oxidative stress link. Eur Respir J. 2009;33:1467–1484.
    1. Ryan S, Taylor CT, McNicholas WT. Systemic inflammation: a key factor in the pathogenesis of cardiovascular complications in obstructive sleep apnoea syndrome? Thorax. 2009;64:631–636.
    1. Rasouli N, Kern PA. Adipocytokines and the metabolic complications of obesity. J Clin Endocrinol Metab. 2008;93:S64–73.
    1. Bansilal S, Farkouh ME, Fuster V. Role of insulin resistance and hyperglycemia in the development of atherosclerosis. Am J Cardiol. 2007;99:6B–14B.
    1. WHO Global Database on Body Mass Index an interactive surveillance tool for monitoring nutrition transition. accessed 2009 Jul 27.
    1. Braunersreuther V, Zernecke A, Arnaud C, Liehn EA, Steffens S, et al. Ccr5 but not Ccr1 deficiency reduces development of diet-induced atherosclerosis in mice. Arterioscler Thromb Vasc Biol. 2007;27:373–379.
    1. Herder C, Peltonen M, Koenig W, Kraft I, Muller-Scholze S, et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes. 2006;55:2340–2346.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다